NCT01173341
Cardiotoxicity of Cancer Therapy (CCT)
Enrolling by Invitation
Not specifiedAges 18+ObservationalAbramson Cancer Center at Penn MedicineInvestigator-initiated
~700 participants
Updated 2026-02-09 on ClinicalTrials.gov
What's tested:EchocardiographyBlood CollectionSymptoms Questionnaire
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cardiac dysfunction or signs or symptoms of heart failure
Measured over 15 years
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Bonnie Ky, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 18 years or older
HER-2 positive breast cancer designated to receive trastuzumab chemotherapy with or without prior exposure to anthracycline-based chemotherapy
Non-HER-2 positive breast cancer designated to receive treatment with an anthracycline-containing regimen
Exclusion
Other contraindications to trastuzumab or anthracycline chemotherapy.
Vulnerable populations
What this trial measures
- Cardiac dysfunction or signs or symptoms of heart failure15 years
Cardiac dysfunction. as defined according to the Cardiac Review and Evaluation Committee (CREC) criteria as a decline in LVEF of 10% to less than 55% without signs or symptoms